OTC Stockz
No Result
View All Result
Sunday, March 26, 2023
  • Login
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education
OTC Stockz
No Result
View All Result
Home Micro Caps

4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial – 4D Molecular Therapeutics (NASDAQ:FDMT)

by OTC Stockz
November 14, 2022
in Micro Caps
Reading Time: 1 min read
0 0
A A
0
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial – 4D Molecular Therapeutics (NASDAQ:FDMT)
Share on FacebookShare on Twitter




4D Molecular Therapeutics Inc FDMT announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD). 
4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported.
No clinically significant intraocular inflammation, endophthalmitis, retinal vasculitis, retinal artery occlusion, choroidal effusions, and hypotony were reported to date.
Also see: 4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment.
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high-need patients who, in the 12 months preceding trial enrollment, had a mean annualized anti-VEGF injection rate of ~11.
Following intravitreal 4D-150, the annualized anti-VEGF injection rate was reduced by 96.7%.
80% of patients have remained anti-VEGF injection-free, with a follow-up of ~40, 36, 32, or 16 weeks.
The company expects to initiate enrollment in the randomized Phase 2 stage of the trial in Q1 2023. 
Additional clinical data from all three Dose Exploration cohorts on this trial is expected in Q2 2023.
Price Action: FDMT shares are up 8.11% at $13.52 on the last check Monday.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

No Result
View All Result
  • Trending
  • Comments
  • Latest
Over the counter stocks (OTC Stock)

The role of market makers in over the counter stocks (OTC Stocks)

March 6, 2023
5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks

5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks

February 27, 2023
Why Are Stocks Down Today?

The Future of OTC Stocks: Navigating the Changing Landscape of Over-the-Counter Investments

February 13, 2023
Over the counter stocks (OTC Stock)

The Benefits of Investing in Over-The-Counter (OTC) Stocks

February 10, 2023
Over the counter stocks (OTC Stock)

Breaking Down the World of Over-the-Counter Stocks (OTC Stock): A Comprehensive Guide

February 10, 2023
In the penny stock market, Xcelerate, Inc. (OTC: XCRT) is emerging as a top Healthcare Services stock to watch in 2022. 

Fabian Urquijo Joins the Advisory Board of Xcelerate, Inc. (OTCMKT: XCRT)

February 2, 2023
OTC Markets Group Welcomes M.O.B.A. Network to OTCQX

Drive Shack Inc. Joins the OTCQX Best Market

January 31, 2023
New York Considers Bill to Establish Cryptocurrency as a Form of Payment for State Agencies

New York Considers Bill to Establish Cryptocurrency as a Form of Payment for State Agencies

January 30, 2023
OTC Stockz

Get the latest news and follow the coverage of OTC Stocks, Micro Caps, Cryptocurrency, NFTs and more from the top trusted sources.

CATEGORIES

  • Cryptocurrency
  • Micro Caps
  • NFTs
  • OTC Stocks
  • Stock Market
  • Stock Market Education
  • Trending
  • Writers Analysis

LATEST UPDATES

  • The role of market makers in over the counter stocks (OTC Stocks)
  • 5 Common Mistakes to Avoid When Investing in Over the Counter (OTC) Stocks
  • Home
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 OTC Stockz.
OTC Stockz is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • OTC Stocks
  • Micro Caps
  • Stocks
  • Cryptocurrency
  • NFTs
  • Education

Copyright © 2022 OTC Stockz.
OTC Stockz is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Verified by MonsterInsights